Cargando…
EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis
Reactivation of apoptotic pathways is an attractive strategy for patients with treatment-resistant B-cell lymphoma. The tumor suppressor, p53 is central for apoptotic response to multiple DNA damaging agents used to treat aggressive B-cell lymphomas, including etoposide. It has been demonstrated tha...
Autores principales: | Smonskey, Matthew, Lasorsa, Elena, Rosario, Spencer, Kirk, Jason S., Hernandez-Ilizaliturri, Francisco J., Ellis, Leigh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751913/ https://www.ncbi.nlm.nih.gov/pubmed/26973857 |
Ejemplares similares
-
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies
por: Lasorsa, E, et al.
Publicado: (2015) -
Etoposide Induces Nuclear Re-Localisation of AID
por: Lambert, Laurens J., et al.
Publicado: (2013) -
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
por: Singh, Anil R., et al.
Publicado: (2020) -
An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
por: Doyle, L. A., et al.
Publicado: (1995) -
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)